Repligen RGEN 深 滬
已收盤 11-06 16:00:00 美东时间
173.49
+5.010
+2.97%
華盛通- 最 高175.00
- 今 開169.35
- 成交量 106.99万股
- 最 低 168.05
- 昨 收 168.48
- 總市值 110.90亿
- 52周最高 198.87
- 市盈率 靜 200.71
- 換手率 1.67%
- 52周最低 100.99
- 委 比 -88.68%
- 總股本 6392.37万
- 歷史最高 327.32
- 量 比 0.57
- 振 幅 4.13%
- 歷史最低 2.90
- 每 手 1
- 風險率 23.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Repligen Issues $1 Billion Convertible Notes, Restructures Debt
Repligen ( ($RGEN) ) has shared an announcement. On November 6, 2026, Repligen ...
今天 05:42
Repligen Corporation to Present at Jefferies Global Healthcare Conference
Repligen Corporation will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and CEO, will join an analyst-led discussion on November 18 at 2:00 p.m. GMT. A live webcast will be available through Repligen’s Investor Relations website, with a replay option for a limited time. Repligen is a global bioprocessing company focused on developing innovative technologies to support biologic drug manufactur...
11-04 12:00
Repligen Corporation收涨3.08%，成交额1.82亿美元
11月4日，Repligen Corporation（RGEN）收涨3.08%，报178.27美元，成交额1.82亿美元，市值113.18亿美元。 行情数据 ...
11-04 05:51
财报速睇 | Repligen 2026财年Q3营收2.09亿美元，同比增长10.9%；归母净利润亏损0.38亿美元，由盈转亏
华盛资讯10月31日讯，Repligen公布2026财年Q3业绩，公司Q3营收2.09亿美元，同比增长10.9%，归母净利润亏损0.38亿美元，由盈转亏。
10-31 04:16
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
Repligen Corporation announced the issuance of $1.0 billion in new 0.25% Convertible Senior Notes due 2031, with approximately $541.4 million exchanged for $456.8 million of its outstanding 1.00% Convertible Senior Notes due 2028, and $458.6 million raised through cash subscriptions. The new notes have an initial conversion price of $226.37 per share, a 20% premium over the October 29 closing price. Repligen plans to use $120 million of the net p...
10-30 10:00
美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
Repligen shares are trading lower despite reporting better-than-expected Q3 results and raising FY26 guidance, as the company posted a GAAP net loss due to an intangible asset impairment charge, compared with a profit a year ago.
Repligen shares are trading lower despite reporting better-than-expected Q3 results and raising FY26 guidance, as the company posted a GAAP net loss due to an intangible asset impairment charge, compared with a profit a year ago.
10-28 03:48
财报速睇 | Repligen 2026财年Q3营收2.09亿美元，同比增长10.9%；归母净利润亏损0.38亿美元，由盈转亏
华盛资讯10月27日讯，Repligen公布2026财年Q3业绩，公司Q3营收2.09亿美元，同比增长10.9%，归母净利润亏损0.38亿美元，由盈转亏。
10-27 19:17
Repligen Raises FY2026 Adj EPS Guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 Est; Raises FY2026 Sales Guidance from $813.000M-$835.000M to $844.000M-$852.000M vs $829.693M Est
Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 analyst estimate. Raises FY2026 sales outlook from $813.000 million-$835.000 million to $844.000 million-$852.000 million vs $829.693 million estimate.
10-27 19:01
Repligen Corporation收跌1%，成交额1.88亿美元
10月24日，Repligen Corporation（RGEN）收跌1%，报176.93美元，成交额1.88亿美元，市值112.33亿美元。 行情数据 • 开...
10-24 04:53
